Key result
Blocking renin-angiotensin system pathways decreases atherosclerotic plaque progression and ischemic events based on animal and human trials.
The renin-angiotensin system plays a central role in atherothrombotic disease, and its blockade is effective in decreasing plaque progression and ischemic events.
Supports RAS blockade to limit plaque progression and events; leaves open optimal strategies for prospective validation.
The renin-angiotensin system plays a central role in the pathogenesis of cardiovascular disease. At the molecular and cellular levels, angiotensin II, the main effector peptide of the system, stimulates key components of atherosclerosis. Trials in animals and humans indicate that blocking renin-angiotensin system pathways decreases atherosclerotic plaque progression and ischemic events. This review provides a broad overview of the entire role of the renin-angiotensin system in atherothrombotic disease, ranging from molecular pathways to human genetics to the latest clinical trials.
No takes yet. Share an insight, caveat, or question.
Jacoby et al. (2003) conducted a review in Atherothrombotic disease. Renin-angiotensin system blockade was evaluated. Blocking renin-angiotensin system pathways decreases atherosclerotic plaque progression and ischemic events based on animal and human trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: